

AMERICAN VIETNAMESE BIOTECH INC

Audited Separate Financial Statements
for the fiscal year ended December 31st, 2025




TABLE OF CONTENTS

	Pages
REPORT OF THE BOARD OF DIRECTORS	1 - 2
INDEPENDENT AUDIT REPORT	3 - 5
SEPARATE STATEMENT OF FINANCIAL POSITION	
Separate Statement of Financial position	6 - 7
Separate Statement of Income	8
Separate Statement of Cash flows	9 - 10
Notes to the Separate Financial statements	11 - 37

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan My Ward, Ho Chi Minh City

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors of American Vietnamese Biotech Inc (hereinafter referred to as the "Company") presents its Report together with its separate Financial Statements for the fiscal year ended December 31st, 2025.

COMPANY INFORMATION

American Vietnamese Biotech Inc was established under the Business Registration Certificate No. 3800237998 issued by the Department of Planning and Investment of Ho Chi Minh City for the first time on August 26th, 2002. During its operation, the Company has changed its business registration certificate 24 times. The 24th amended joint-stock company enterprise registration certificate was issued on August 17th, 2025.

BOARD OF DIRECTORS

Members of the Board of Directors and the Board of Directors of the Company during the year and up to the date of this report include:

Board of Directors

Full name	Position	Date of Appointment/ Dismissal
Mr. Nakatani Yoshitaka	Chairman	
Mrs. Dang Nhi Nuong	Members	
Mrs. Le Khanh Nguyen	Members	

Supervisory Board

Full name	Position	Date of Appointment/ Dismissal
Mrs. Le Thi Huong	Head of Department	
Mrs. Nguyen Huong Giang	Members	
Mr. Le Huu Tri	Members	Appointed on 29/7/2025
Mrs. Vu Thu Thuy	Members	Dismissal on 29/7/2025

Board of Directors and Chief Accountant

Full name	Position	Date of Appointment/ Dismissal
Mrs. Dang Nhi Nuong	Director	
Mrs. Le Thi Viet Ha	Chief Accountant	Dismissal on 11/6/2025
Mrs. Dang Thi Thanh Tuyen	Chief Accountant	Appointed on 11/6/2025 Dismissal on 17/10/2025
Mrs. Nguyen Thu Huyen	Chief Accountant	Appointed on 17/10/2025

Legal representation

The legal representative of the Company in the period and at the time of making this report is as follows: Ms. Dang Nhi Nuong – Director of the Company.

EVENTS ARISING AFTER THE END OF THE FISCAL YEAR

No significant event has occurred since the end of the fiscal year ended December 31st, 2025 that would require adjustment or disclosure in the Notes to the Separate Financial Statements.

AUDITOR

International Auditing and Valuation Co., Ltd. is appointed as the auditor to audit the Company's Separate Financial Statements for the financial year ended December 31st, 2025.

REPORT OF THE BOARD OF DIRECTORS (CONTINUED)

DISCLOSURE OF MANAGEMENT'S RESPONSIBILITIES FOR SEPARATE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for preparing its own financial statements that truthfully and reasonably reflect the Company's own financial situation as at December 31st, 2025, as well as its own business results and its own cash flow situation for the fiscal year ending on the same date. In accordance with accounting standards, accounting regimes for Vietnamese enterprises and legal regulations related to the preparation and presentation of separate financial statements. In preparing this separate financial statement, management is required to:

- Select appropriate accounting policies and apply them consistently;
- Make judgments and estimates in a reasonable and prudent manner;
- Specify whether appropriate accounting principles are followed, whether there are material deviations that need to be disclosed and explained in the separate financial statements;
- Prepare separate financial statements on the basis of continuous operation, except in cases where it cannot be assumed that the Company will continue to operate its business; and
- Design and implement an effective internal control system for the purpose of preparing and presenting separate financial statements in a reasonable manner to limit risk and fraud.

The Company's management is responsible for ensuring that the accounting books are properly recorded to reasonably reflect the Company's own financial position at any given time and for ensuring that the Separate Financial Statements comply with accounting standards, the accounting regime of Vietnamese enterprises and legal regulations related to the preparation and presentation of separate financial statements. Management is also responsible for ensuring the safety of the Company's assets and taking appropriate measures to prevent and detect fraud and other misconduct.

The Board of Management confirms that the Company has complied with the above-mentioned requirements in the preparation of its own financial statements.

APPROVAL OF SEPARATE FINANCIAL STATEMENTS

The Board of Directors approves the attached separate financial statements. The separate financial statements have honestly and reasonably reflected the Company's own financial position as at December 31st, 2025, as well as its own business results and separate cash flows for the financial year ended on the same day, in accordance with accounting standards, the current accounting regime for Vietnamese enterprises and legal regulations related to the preparation and presentation of separate financial statements.

COMMITMENT TO DISCLOSURE

The Board of Directors commits that the Company complies with the Prime Minister's Decree No. 155/2020/ND-CP dated 31/12/2020 detailing the implementation of a number of articles of the Law on Securities and the Company does not violate the obligation to disclose information as prescribed in Circular No. 96/2020/TT-BTC dated 16/11/2020 of the Ministry of Finance guiding the disclosure of information on the Securities Market and Circular No. 68/2024/TT-BTC dated 18/09/2024 of the Ministry of Finance amending and supplementing a number of articles of circulars regulating securities trading on the securities trading system; clearing and settlement of securities transactions; activities of securities companies and information disclosure on the securities market.

On behalf of the Board of Directors,



Mrs. Dang Nhi Nuong

Director

Ho Chi Minh City, May 15th, 2026

No. 1004/2026/BCTC/IAV

INDEPENDENT AUDIT REPORT

To: **Shareholders**
Board of Directors, Supervisory Board and Board of Directors
American Vietnamese Biotech Inc

We have audited the accompanying separate financial statements of **American Vietnamese Biotech Inc** (hereinafter referred to as the "Company"), prepared on May 15th, 2026, from pages 6 to 37, including the Separate Statement of Financial Position as at December 31st, 2025, Separate statement of income, Separate statement of cash flows for the fiscal year ending on the same day and accompanying Notes to the separate financial statements.

Responsibilities of the Board of Directors

The Company's Board of Directors is responsible for the preparation and honest and reasonable presentation of the Company's own financial statements in accordance with accounting standards, Vietnamese corporate accounting regimes and legal regulations related to the preparation and presentation of financial statements and is responsible for the internal controls that the Director determines are necessary to ensure that the preparation and presentation of the Separate Financial Statements are free from material errors due to fraud or mistakes.

Responsibilities of the Auditor

It is our responsibility to provide an opinion on our own Financial Statements based on the results of the audit. We have conducted audits in accordance with Vietnam Auditing Standards. These Standards require us to comply with standards and regulations on professional ethics, to plan and conduct an audit in order to achieve reasonable assurance as to whether the Company's own financial statements remain materially flawed.

Audit work includes carrying out procedures to collect audit evidence of figures and explanations on separate financial statements. Audit procedures are selected based on the auditor's judgment, including an assessment of the risk of material misstatements in the Separate Financial Statements due to fraud or error. In assessing these risks, the auditor reviewed the Company's internal controls in relation to the preparation and presentation of honest and reasonable Separate Financial Statements in order to design audit procedures in accordance with the actual situation, but did not intend to give an opinion on the effectiveness of the Company's internal controls. The audit work also includes assessing the appropriateness of the accounting policies applied and the reasonableness of the Management's accounting estimates as well as evaluating the overall presentation of the Separate Financial Statements.

We are confident that the audit evidence we have collected is adequate and appropriate as the basis for our audit opinion.

INDEPENDENT AUDIT REPORT (CONTINUED)

Audit Opinion

In our opinion, the accompanying separate financial statements have honestly and reasonably reflected the material aspects, the financial situation of Viet My Pharmaceutical and Medical Equipment Manufacturing and Trading Joint Stock Company as at 31/12/2025 as well as separate statement of income and as separate statement of cash flow for the fiscal year ending date, in accordance with the Accounting Standards, the Accounting Regime (enterprises) of Vietnam and legal regulations related to the preparation and presentation of separate financial statements.

Issues to be emphasized

As presented in Explanation No. 4.16, As of December 31st, 2025, the Company's loan at Viet Capital Commercial Joint Stock Bank is VND 23,126,095,827 which is overdue. At the time of this report, the above debt was overdue. The time to apply for an extension according to the Company's Official Letter No. 05/2024/CV-AMV is October 2024 and has been approved by Viet Capital Commercial Joint Stock Bank according to Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, up to now, the Company has not paid off the principal debt mentioned above, the Company is continuing to work with the Bank to apply for a debt extension.

Our audit opinion is not relevant to this issue of emphasis.

Other issues

The separate financial statements for the fiscal year ended December 31st, 2024 of American Vietnamese Biotech Inc have been audited by the Auditor and other auditing firms. The Auditor has issued an Exception Opinion dated 28/8/2025, with the basis of the Exception Audit Opinion as follows:

- We were unable to participate in witnessing the cash inventory on December 31st, 2024, the cash fund balance was VND 290,950,121 because at that time we had not been appointed as an auditor. Therefore, we do not comment on the accuracy, availability and completeness of cash at the time stated above.
- A number of associated companies have been established but have not yet formed or insignificant assets in service of production and business activities. The amount of capital contribution to these companies is 60,900,000,000 VND. By the applicable audit procedures, we do not have sufficient grounds to assess the reasonableness of the above investments as well as their impact on the financial statements in 2024.
- The company has invested and installed machinery and equipment, RIS-PACS medical image storage and transmission software system under lease contracts, cooperation with hospitals and medical centers with an investment cost of 80,255,898,895 VND as of 31/12/2024 (of which the value handed over to the hospital for use is 59,564,895,987 VND, not handed over to the hospital is 20,691,002,908 VND). In some hospitals, there is already revenue but due to the lack of specific and consistent guidance on payment for diagnostic imaging services based on the PACS system, the Company still does not have enough reliable basis to fully determine the economic benefits obtained from leasing. cooperation mentioned above. However, the Company has recorded depreciation expense for the assets handed over in the business results of the years, the accumulated depreciation value as of December 31st, 2024 is VND 20,811,796,801 (of which accumulated until December 31, 2023 is VND 16,526,054,590, depreciation in 2024 is 4,285,742,211 VND). By applicable audit procedures, we have not determined their impact on the financial statements for the financial year ended December 31st, 2024.

INDEPENDENT AUDIT REPORT (CONTINUED)

For the above issues. The company has carried out a cash inventory on 31/12/2025; The auditor also performed an additional inventory at the time of the audit. At the time of issuance of this report, the associated companies are operating stably and preparing to operate; some investments have been recovered based on agreements and commitments to terminate investments. The lease and cooperation contracts with the hospital have been agreed in writing on profit distribution and have been implemented and accounted for by the Company in accordance with these agreements and commitments. Accordingly, the above issues no longer affect the attached 2025 separate financial statements.



Đo Thị Thanh Huyền
Deputy Director
Audit Certificate:
Number: 2421-2024-283-1

INTERNATIONAL AUDITING AND VALUATION CO., LTD

Hanoi, Vietnam
May 15, 2026

Nguyen Hai Phuong
Auditor
Certificate of Audit:
Number: 1329-2023-283-1

SEPARATE STATEMENT OF FINANCIAL POSITION

As at December 31st, 2025

ASSETS	Code	Note	Closing balance VND	Opening balance VND
A. CURRENT ASSETS	100		99,882,090,206	181,924,053,900
I. Cash and cash equivalents	110	4.1	1,972,095,736	2,123,348,100
1. Cash	111		1,972,095,736	2,123,348,100
II. Short-term financial investment	120		-	-
III. Short-term receivables	130		81,433,710,997	169,243,010,523
1. Short-term trade receivables	131	4.3	18,793,097,280	153,370,344,475
2. Short-term prepayments to suppliers	132	4.4	17,757,003,704	9,524,350,514
3. Short-term loan receivable	135		-	500,000,000
4. Other short-term receivables	136	4.5	45,142,935,141	6,107,640,662
5. Provision for short-term doubtful debts	137	4.11	(259,325,128)	(259,325,128)
IV. Inventories	140	4.6	16,284,033,892	10,357,695,277
1. Inventories	141		16,284,033,892	10,357,695,277
V. Other short-term assets	150		192,249,581	200,000,000
1. Short-term prepaid expenses	151	4.7	90,482,526	-
2. Deductible VAT	152		95,603,627	-
3. Taxes and other receivables from State budget	153	4.13	6,163,428	200,000,000
B. NON-CURRENT ASSETS	200		1,526,680,849,490	1,485,939,099,062
I. Long-term receivables	210		125,727,000,000	-
1. Other long-term receivables	216	4.5	125,727,000,000	-
II. Fixed assets	220		59,898,270,445	65,432,066,344
1. Tangible fixed assets	221	4.8	27,087,910,847	26,678,967,158
- Historical cost	222		54,860,290,809	50,034,090,809
- Accumulated depreciation	223		(27,772,379,962)	(23,355,123,651)
2. Intangible fixed assets	227	4.9	32,810,359,598	38,753,099,186
- Historical cost	228		59,564,895,987	59,564,895,987
- Accumulated amortization	229		(26,754,536,389)	(20,811,796,801)
III. Investment Properties	230		-	-
IV. Long-term assets in progress	240	4.10	20,691,865,470	20,691,002,908
1. Construction in progress	242		20,691,865,470	20,691,002,908
V. Long-term investments	250	4.2	1,320,338,277,325	1,399,802,674,180
1. Investments in subsidiaries	251		1,254,740,000,000	1,284,140,000,000
2. Investments in joint ventures and associates	252		153,300,000,000	153,300,000,000
3. Provision for devaluation of long-term investments	254		(87,701,722,675)	(37,637,325,820)
VI. Other long-term assets	260		25,436,250	13,355,630
1. Long-term prepaid expenses	261	4.7	25,436,250	13,355,630
TOTAL ASSETS(270 = 100 + 200)	270		1,626,562,939,696	1,667,863,152,962

SEPARATE STATEMENT OF FINANCIAL POSITION (continued)

As at December 31st, 2025

CAPITAL	Code	Note	Closing balance VND	Opening balance VND
C. LIABILITIES	300		124,569,205,721	122,958,438,171
I. Current liabilities	310		124,569,205,721	122,958,438,171
1. Short-term trade payables	311	4.12	917,335,164	1,149,011,676
2. Taxes and other payables to State budget	313	4.13	29,144,742	898,719,173
3. Payables to employees	314		562,519,653	593,880,249
4. Short-term accrued expenses	315	4.14	23,968,555,935	19,760,461,246
5. Other short-term payables	319	4.15	75,965,554,400	75,931,270,000
6. Short-term borrowings and finance lease liabilities	320	4.16	23,126,095,827	24,625,095,827
II. Non-current liabilities	330		-	-
D. OWNER'S EQUITY	400	4.17	1,501,993,733,975	1,544,904,714,791
I. Owner's equity	410		1,501,993,733,975	1,544,904,714,791
1. Contributed capital	411		1,311,056,500,000	1,311,056,500,000
- Ordinary shares with voting rights	411a		1,311,056,500,000	1,311,056,500,000
2. Share Premium	412		(395,300,000)	(395,300,000)
3. Retained earnings	421		191,332,533,975	234,243,514,791
- Retained earnings accumulated till the end of the previous year	421a		234,243,514,791	246,895,237,887
- Retained earnings of the current year	421b		(42,910,980,816)	(12,651,723,096)
II. Non-business funds and other funds	430		-	-
TOTAL CAPITAL (440=300+400)	440		1,626,562,939,696	1,667,863,152,962

Preparer
Tran Hang Nga

Chief Accountant
Nguyen Thu Huyen

Director
Dang Nhi Nuong
Ho Chi Minh City, Vietnam
May 15, 2026



SEPARATE STATEMENT OF INCOME

For the fiscal year ending December 31st, 2025

ITEMS	Code	Note	This year VND	Previous year VND
1. Revenue from sales of goods and rendering of services	01	5.1	26,092,083,075	169,364,910,851
2. Revenue deductions	02	5.2	329,337,871	-
3. Net revenue from sales of goods and rendering of services (10 = 01 - 02)	10		25,762,745,204	169,364,910,851
4. Cost of goods sold and services rendered	11	5.3	23,253,299,467	160,394,730,660
5. Gross profit from sales of goods and rendering of services (20 = 10 - 11)	20		2,509,445,737	8,970,180,191
6. Financial income	21	5.4	17,010,120,993	10,000,513,202
7. Financial expense	22	5.5	54,594,491,544	29,864,843,530
In which: Interest expenses	23		4,530,094,689	5,638,032,048
8. Selling expense	25	5.6	135,413,326	321,072,342
9. General and administrative expense	26	5.7	7,714,636,158	5,325,865,947
10. Net profit from operating activities {30 = 20 + (21 - 22) - (25 + 26)}	30		(42,924,974,298)	(16,541,088,426)
11. Other income	31	5.8	140,227,540	3,924,305,576
12. Other expenses	32	5.9	126,234,058	34,940,246
13. Other Profits (40 = 31 - 32)	40		13,993,482	3,889,365,330
14. Total net profit before tax (50=30+40)	50		(42,910,980,816)	(12,651,723,096)
15. Current corporate income tax expense	51	5.10	-	-
16. Deferred corporate income tax expense	52		-	-
17. Profit after corporate income tax (60 = 50 - 51 - 52)	60		(42,910,980,816)	(12,651,723,096)
18. Basic earnings per share	70		(632)	(97)
19. Diluted earnings per share	71		(632)	(97)



Preparer
Tran Hang Nga



Chief Accountant
Nguyen Thu Huyen



Director
Dang Nhi Nuong
Ho Chi Minh City, Vietnam
May 15, 2026

SEPARATE STATEMENT OF CASH FLOWS*For the fiscal year ending December 31st, 2025**(Applying indirect method)*

Items	Code	Note	This year VND	Previous year VND
I. CASH FLOWS FROM OPERATING ACTIVITIES				
1. Profit before tax	01		(42,910,980,816)	(12,651,723,096)
2. Adjustment for:				
- Depreciation and amortization of fixed assets and investment properties	02		10,712,195,899	9,667,514,548
- Provisions	03		50,064,396,855	24,410,761,325
- Gains / losses from investment	05		(17,150,120,993)	(13,904,402,106)
- Interest expense	06		4,530,094,689	5,638,032,048
3. Operating profit before changes in working capital	08		5,245,585,634	13,160,182,719
- Increase or decrease in receivables	09		(43,319,467,529)	(2,658,596,511)
- Increase or decrease in inventories	10		(5,926,338,615)	150,614,916,371
- Increase or decrease in payables (excluding interest payable/ corporate income tax payable)	11		(1,420,327,139)	(3,462,780,691)
- Increase or decrease in prepaid expenses	12		(102,563,146)	47,739,316
- Interest paid	14		-	(23,631,642)
- Corporate income tax paid	15		-	(200,000,000)
Net cash flow from operating activities	20		(45,523,110,795)	157,477,829,562
II. CASH FLOWS FROM INVESTING ACTIVITIES				
1. Purchase or construction of fixed assets and other long-term assets	21		(5,179,262,562)	(13,224,968,137)
2. Proceeds from disposals of fixed assets and other long-term assets	22		140,000,000	2,518,500,000
3. Loans and purchase of debt instruments from other entities	23		-	(10,030,000,000)
4. Collection of loans and resale of debt instrument of other entities	24		500,000,000	9,530,000,000
5. Equity investments in other entities	25		-	(148,400,000,000)
6. Proceeds from equity investment in other entities	26		29,400,000,000	
7. Interest and dividend received	27		22,010,120,993	5,000,513,202
Net cash flow from investing activities	30		46,870,858,431	(154,605,954,935)
III. CASH FLOWS FROM FINANCING ACTIVITIES				
1. Repayment of principal	34		(1,499,000,000)	(7,153,437,823)
Net cash flow from financing activities	40		(1,499,000,000)	(7,153,437,823)

SEPARATE STATEMENT OF CASH FLOWS (CONTINUED)*For the fiscal year ending December 31st, 2025**(by indirect method)*

Items	Code	Note	This year VND	Previous year VND
Net cash flows in the year (50=20+30+40)	50		(151,252,364)	(4,281,563,196)
Cash and cash equivalents at the beginning of the year	60	4.1	2,123,348,100	6,404,911,296
Cash and cash equivalents at the end of the year (70=50+60+61)	70	4.1	1,972,095,736	2,123,348,100



Preparer
Tran Hang Nga



Chief Accountant
Nguyen Thu Huyen



Director
Dang Nhi Nuong
Ho Chi Minh City, Vietnam
May 15, 2026

NOTES TO THE SEPARATE FINANCIAL STATEMENTS*For the fiscal year ending December 31st, 2025*

These disclosures are a constituent part and should be read simultaneously with separate financial statements attached.

1. GENERAL INFORMATION OF THE COMPANY**1.1. Forms of ownership**

American Vietnamese Biotech Inc (hereinafter referred to as the "Company") is a joint stock company established and operating in Vietnam under the Enterprise Registration Certificate No. 3800237998 first registered on August 26th, 2002 and amended for the 24th time on August 17th, 2025 by the Department of Planning and Investment. Ho Chi Minh City.

The Company's head office is at: 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai, Tan Phu Ward, Ho Chi Minh City.

The actual charter capital contributed according to the Company's Business Registration Certificate until 31/12/2025 is 1,311,056,500,000 VND, divided into 131,105,650 shares with a par value of 10,000 VND/share.

The total number of employees of the Company as of December 31st, 2025 is 28 people (as of December 31st, 2024 is 30 people).

1.2. Business Areas

The Company's main production and business activities are trading in medical equipment and medical testing chemicals

1.3. Main production and business activities

- Retail of medicines, medical instruments, cosmetics, and hygiene items in specialized stores
Details: pharmaceutical trading, purchase and sale of medical equipment, medical testing instruments and chemicals;
- Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments
Details: Manufacturing of medical testing instruments;
- Manufacture of medicines, medicinal chemicals and medicinal materials
Details: Production and trading of vaccines and medical biologicals;
- Production of cosmetics, soaps, detergents, polishes and hygiene products; Agents, brokers, auctions
Details: Agents for consignment of goods, production of plastic products;
- Trading in real estate, land use rights belonging to owners, users or tenants
Details: Real estate business;
- Water exploitation, treatment and supply; Drainage and wastewater treatment; Scrap recycling; Pollution treatment and other waste management activities;
- Other professional, scientific and technological activities have not been classified anywhere
Details: Technology transfer;
- Other business lines specified in the Enterprise Registration Certificate.
- Main business activities: Trading in medical equipment and medical testing chemicals.

1.4. Normal business and production cycle

The Company's normal production and business cycle is carried out for a period of no more than 12 months.

1.5. Corporate Structure

Subsidiaries

Company Name	Head Office Address	Ownership Ratio	Voting Rate	Main business activities
Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam	83,33%	83,33%	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment Manufacture of medicines, medicinal chemicals and medicinal materials.
Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Cluster, Ba Che Commune, Quang Ninh Province, Vietnam	99,00%	99,00%	Manufacture of ovens, smelting furnaces and kilns
Golab Uong Bi Testing Center Joint Stock Company	Group 4, Zone 4, Bai Chay Ward, Quang Ninh Province	98,00%	98,00%	General and Specialty Clinics
Song Hau New Technology Research and Application Joint Stock Company	Song Hau Industrial Park Phase 1, Chau Thanh Commune, Can Tho City, Vietnam	98,00%	98,00%	Manufacture of ovens, smelting furnaces and kilns
Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh Street, Cau Buu, Kien Hung Ward, Hanoi City, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Hoa Binh Clinic Joint Stock Company	1st Floor, No. 83 Cu Chinh Lan Street, Group 13, Hoa Binh Ward, Phu Tho Province, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Gia Lam High-tech Clinic Joint Stock Company	18 BT5 Phap Van - Tu Hiep Urban Area, Yen So Ward, Hanoi City, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Can Tho Medicare Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Hau Giang Medicare Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Area 4, Vi Thanh Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Soc Trang Medicare Clinic Joint Stock Company	1st Floor, 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City, Vietnam	98,00%	98,00%	General, specialty, and dental clinics
Golab Nga Bai Testing Center Joint Stock Company	No. 222, 30/4 Street, Area 5, Nga Bai Ward, Can Tho City	98,00%	98,00%	General, specialty, and dental clinics
Leopard Solutions Joint Stock Company	No. 34, Street 79, Hamlet Dinh, Cu Chi Commune, Ho Chi Minh City.	75,00%	75,00%	Microcomputer Programming
Vietnam National Software Manufacturing Joint Stock Company (*)	No. 36 BT5 Phap Van - Tu Hiep Urban Area, Hoang Mai Ward, Hanoi City	98,00%	98,00%	Microcomputer Programming

(*) Resolution of the Board of Directors No. 2502.01/2025/NQ-HDQT dated 25/02/2025 on the divestment of investment in Vietnam National Software Manufacturing Joint Stock Company. At the time of issuance of this report, the company has divested all capital in this subsidiary.

The subsidiaries are operating normally.

Associate companies: Details in Description 4.2

Dependent cost-accounting dependent units:

Company Name	Address	Main Activities
Representative Office of American Vietnamese Biotech Inc	A30-A31 D1 Street, Tan Hai Minh Residential Area, KP1, Thu Duc Ward, Ho Chi Minh City.	Pharmaceutical trading, purchase and sale of medical testing equipment, instruments and chemicals (Normal operation)
Branch of American Vietnamese Biotech Inc	Vinaconex Diamond Building, 459 C Bach Mai, Bach Mai Ward, Hanoi City, Vietnam.	Pharmaceutical trading, purchase and sale of medical testing equipment, instruments and chemicals (Normal operation)

1.6. Statement of Comparability of Information on Separate Financial Statements

The figures presented in the Financial Statements for the fiscal year ended December 31st, 2025 are comparable to the corresponding figures of the previous year.

2. BASIS FOR PREPARING SEPARATE FINANCIAL STATEMENTS AND THE FINANCIAL YEAR

2.1 Basis for preparing separate financial statements

The enclosed separate financial statements shall be presented in Vietnam Dong (VND), on the principle of Historical cost and in accordance with accounting standards, accounting regimes for Vietnamese enterprises and legal regulations related to the preparation and presentation of separate financial statements.

The enclosed separate financial statements are not intended to reflect the financial situation, results of business activities and cash flows in accordance with generally accepted accounting principles and practices in countries other than Vietnam.

2.2 Assume continuous operation

There are no events that raise serious doubts about its ability to continue operations and the Company does not intend nor be forced to cease operations, or to significantly reduce the scale of its operations.

2.3 Fiscal Year

The Company's financial year starts on January 01 and ends on December 31 every year.

3 SUMMARY OF MAJOR ACCOUNTING POLICIES

3.1 Accounting estimates

The preparation of separate financial statements in compliance with accounting standards, the accounting regime of Vietnamese enterprises and legal regulations related to the preparation and presentation of separate financial statements requires the Board of Directors to have estimates and assumptions that affect the reporting data on debts, assets and the presentation of liabilities and contingent assets at the date of preparation of the financial statements as well as the reporting figures on revenues and expenses throughout the financial year. Although accounting estimates are made with the best knowledge of management, the actual amounts incurred may differ from the estimates and assumptions made.

3.2 Cash and cash equivalents

Cash and cash equivalents include cash at the fund, demand deposits, short-term investments, are highly liquid, easily converted into cash, and have little risk associated with value fluctuations.

3.3 Financial Investments

Loans

Loans are determined by the cost minus bad debt provisions. The provision for bad debts of the Company's loans is set aside in accordance with current accounting regulations.

Investments in subsidiaries, joint ventures, associations

Investing in Subsidiaries

Subsidiaries are companies controlled by the Company. Control is achieved when the Company has the ability to control the financial policies and operations of the investee companies in order to gain benefits from the activities of these companies.

The company initially recorded the investment in subsidiaries, joint ventures and associates at the original price. The company shall account in the income on the report on the business results of the amount divided from the accumulated net profit of the investee arising after the date of investment. Other amounts received by the Company in addition to the profits shared are considered as the recovery of investments and are recorded as a deduction of the Historical cost of investment.

Investments in subsidiaries, joint ventures, and associated companies are presented in the Balance Sheet at cost minus discount provisions (if any). A provision for the depreciation of investments is made when there is strong evidence that there was a decline in the value of these investments at the end of the accounting period.

3.4 Receivables

Receivables are recoverable amounts of money from customers or other objects. Receivables are presented according to the book value minus bad debt provisions.

A provision for bad debts is made for each bad debt based on the overdue age of the debts or the expected level of possible losses, or receivables that the debtor is unable to pay due to liquidation, bankruptcy or similar difficulties.

3.5 Inventory

Inventory is determined on the basis of the lower price between the Historical cost and the net realizable value. The cost of inventory includes direct material costs, direct labor costs, and overhead production costs, if applicable, to obtain inventory at its current location and state.

The cost of inventory is determined by the weighted average method.

Net realizable value is determined by the estimated selling price minus the estimated costs to complete the product and the marketing, sales, and distribution costs incurred.

The Company's inventory reduction provision is set aside in accordance with current accounting regulations. Accordingly, the Company is allowed to set aside provisions for depreciation of outdated, damaged, poor quality inventories and in case the Historical cost of inventory is higher than the net value that can be realized at the end of the accounting year.

3.6 Tangible fixed assets

Tangible fixed assets are presented at historical cost minus the accumulated depreciation value.

The historical cost of a tangible fixed asset includes the purchase price and all other costs directly related to bringing the asset into a state of readiness for use.

The historical cost of tangible fixed assets made by self-made or self-built includes construction costs, actual production costs incurred plus installation and commissioning costs.

Depreciation of tangible fixed assets is deducted by the straight-line method with the depreciation period estimated as follows:

	This year [Number of years]
Machinery and equipment	05 – 08
Means of transport, transmission	06 – 10

Profits and losses arising from the liquidation and sale of assets are the difference between income from liquidation and the residual value of assets and are recorded in the report on business results.

3.7 Intangible fixed assets

Historical cost of intangible fixed assets includes all costs that enterprises must spend to acquire fixed assets up to the time of putting such assets into a state of readiness for use. Expenses related to intangible fixed assets incurred after initial recognition shall be recognized as production and business expenses in the period unless these expenses are associated with a specific intangible fixed asset and increase the economic benefits from these assets.

When intangible fixed assets are sold or liquidated, the historical cost and accumulated depreciation value are wiped out and the profits and losses arising from the liquidation are recorded as income or expenses for the year.

Intangible fixed assets of enterprises include:

Software Programs

The costs associated with computer software programs are not a part tied to the relevant hardware that is capitalized. The historical cost of the computer software is the total cost that the Company has spent up to the time of putting the software into use. Computer software is depreciated according to the straight-line method for 04 years.

3.8 Prepaid expenses

Prepaid expenses include actual expenses incurred but related to the results of production and business activities of many accounting periods. The Company's prepaid expenses include the following costs: Repair costs, office decoration and others.

3.9 Liabilities and expenses payable

Liabilities and expenses payable are recorded for future amounts payable in relation to goods and services received. Expenses to be paid are recorded based on reasonable estimates of the amount to be paid.

The classification of payables as payables to sellers, payable expenses and other payables shall be carried out according to the following principles:

- Seller payables reflect commercial payables arising from the purchase of goods, services, assets and the seller is an independent entity of the Company.
- Payable expenses reflect amounts payable for goods and services received from the seller or provided to the buyer but not yet paid because there are no invoices or insufficient accounting records and documents and amounts payable to the employee in terms of salary and leave, production and business expenses must be deducted in advance. When such expenses are actually incurred, if there is a difference with the deducted amount, the accountant shall record additional or decreased expenses corresponding to the difference.
- Other payables reflect payables that are not commercial, not related to the purchase, sale or provision of services.

3.10 Loans and liabilities finance lease

Loans are tracked by each lender, each loan contract, and the payable term of the loans. In case of borrowing in foreign currencies, detailed monitoring shall be carried out in the original currency.

3.11 Bonds issued

The book value of a bond is usually reflected on a net basis equal to the value of the bond at par value minus (-) Bond discount plus (+) Bond Extra.

The Company shall monitor the discounts and surcharges for each type of bonds issued and the allocation of each discount and surcharge when determining borrowing costs included in production and business expenses or capitalization in each period, specifically:

- Bond discounts shall be gradually allocated to be included in the borrowing costs of each period throughout the term of the bonds;
- Bond surpluses are allocated gradually to reduce borrowing costs in each period throughout the bond's term.

The allocation of discounts or surcharges by the straight-line method over the life of the bond.

3.12 Owner's equity

The owner's investment capital is recorded according to the actual capital contributed by shareholders.

3.13 Profit distribution

Profit after corporate income tax is distributed to shareholders after setting up funds in accordance with the Company's Charter as well as the provisions of law and has been approved by the General Meeting of Shareholders.

The distribution of profits to shareholders is considered to non-monetary items included in undistributed after-tax profits that may affect cash flow and dividend payability such as interest from revaluation of assets to be contributed to capital, interest on revaluation of monetary items, etc financial instruments and other non-monetary items.

Dividends are recorded as liabilities when they are approved by the General Meeting of Shareholders and notify the closing date of the right to receive dividends of the Vietnam Securities Depository.

3.14 Revenue and income

Revenue from sale of goods and finished products

Revenue from the sale of goods and finished products shall be recorded when the following conditions are simultaneously satisfied:

- The company has transferred most of the risks and benefits associated with ownership of the product or goods to the buyer.
- The company no longer holds the right to manage the goods as the owner of the goods or control of the goods.
- Revenue is determined relatively firmly.
- The company has obtained or will obtain an economic benefit from the sale.
- Identify the costs associated with the sale.

Revenue from financial activities

Interest

Interest is recorded on an accrual basis, determined on the balance of deposit accounts and the actual interest rate in each period.

3.15 Cost of Goods Sold

The cost of goods sold includes the cost of products, goods and services provided in the year and is recorded in accordance with the revenue consumed in the year. The cost of raw materials directly

consumed in excess of the normal level, labor costs, fixed general production costs not allocated to the value of products in the warehouse, must be immediately included in the cost of goods sold (after deducting compensations, if any) even if the products, goods that have not been identified as consumable.

3.16 General and administrative expense

General and administrative expenses reflect actual expenses incurred in the process of general management of the Company, mainly including expenses for salaries of employees and management departments; social insurance, health insurance, trade union funding, unemployment insurance of managers; the cost of office materials; depreciation expenses; contingency costs; outsourced services and other costs.

3.17 Taxes

Corporate income tax represents the total value of the current payable tax amount and the deferred tax amount.

The current tax payable amount is calculated based on taxable income for the year. Taxable income is different from the pre-tax profit presented on the Income Statement because taxable income does not include taxable or deductible income or expenses in other years (including carry-over losses, if any) and does not include non-taxable or non-deductible items.

Deferred income tax is calculated on the difference between the book value and the income tax calculation basis of the assets or liabilities items on the financial statements and is recorded according to the Balance Sheet method. Deferred income tax payable must be recorded for all temporary differences, while deferred income tax assets are only recognized when there is certain that there is sufficient taxable profit in the future to deduct temporary differences.

Deferred income tax is determined at the estimated tax rate that will apply to the year the property is recovered or liabilities are paid. Deferred income tax is recorded in the Statement of Income of Business and is credited to equity only when the tax is related to items recorded directly in equity.

Deferred income tax assets and deferred income tax liabilities payable are offset when the Company has the legal right to set off between the applicable income tax assets and the applicable income tax payable and when the deferred income tax assets and deferred income tax liabilities payable in relation to corporate income tax are administered by the same tax authority and the Company intends to pay the applicable income tax on a net basis.

The determination of the Company's income tax is based on current tax regulations. However, these regulations change from time to time and the final determination of corporate income tax depends on the inspection results of the competent tax authority.

Other taxes are applied in accordance with the applicable tax laws in Vietnam.

3.18 Shareholders

Parties are considered involved if one party has the ability to control or have significant influence over the other party in financial and operational decision-making. Parties are also considered stakeholders if they are jointly controlled or jointly substantially affected.

In considering the relationship of the parties involved, the nature of the relationship is given more emphasis than the legal form

4 ADDITIONAL INFORMATION FOR ITEMS PRESENTED ON A SEPARATE OF FINANCIAL POSITION

4.1 Cash and cash equivalents

	Closing balance VND	Opening balance VND
Cash	581,800,202	290,950,121
Demand deposits	1,390,295,534	1,832,397,979
	1,972,095,736	2,123,348,100

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.2 Financial Investments

	Closing balance			Opening balance		
	Historical cost VND	Provision VND	Fair value VND	Historical cost VND	Provision VND	Fair value VND
<i>Investing in a subsidiary</i>	1,254,740,000,000	(85,256,189,363)		1,284,140,000,000	(36,715,580,781)	
Viet My Hospital Investment Joint Stock Company	250,000,000,000	(25,355,711,237)	(i)	250,000,000,000	(18,079,224,693)	(i)
Ha Long Kyoto Technology Development Joint Stock Company	108,900,000,000	(11,328,152,568)	(i)	108,900,000,000	(8,732,280,347)	(i)
Golab Uong Bi Testing Center Joint Stock Company	49,000,000,000	(8,223,977,360)	(i)	49,000,000,000	-	(i)
Song Hau New Technology Research and Application Joint Stock Company	147,000,000,000	-	(i)	147,000,000,000	-	(i)
Vietnam National Software Manufacturing Joint Stock Company	-	-	(i)	29,400,000,000	-	(i)
Leopard Solutions Joint Stock Company	6,000,000,000	-	(i)	6,000,000,000	-	(i)
Ha Dong Clinic Joint Stock Company	77,420,000,000	(3,534,892,713)	(i)	77,420,000,000	-	(i)
Hoa Binh Clinic Joint Stock Company	122,500,000,000	(6,292,628,345)	(i)	122,500,000,000	(9,904,075,741)	(i)
Viet Tri Clinic Joint Stock Company	106,820,000,000	(22,622,777,665)	(i)	106,820,000,000	-	(i)
Gia Lam High-tech Clinic Joint Stock Company	77,420,000,000	(4,297,373,667)	(i)	77,420,000,000	-	(i)
Can Tho Medicare Clinic Joint Stock Company	77,420,000,000	(1,709,084,274)	(i)	77,420,000,000	-	(i)
Hau Giang Medicare Clinic Joint Stock Company	77,420,000,000	(1,891,591,534)	(i)	77,420,000,000	-	(i)
Soc Trang Medicare Clinic Joint Stock Company	77,420,000,000	-	(i)	77,420,000,000	-	(i)

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

	Closing balance			Opening balance		
	Historical cost VND	Provision VND	Fair value VND	Historical cost VND	Provision VND	Fair value VND
Golab Nga Bai Testing Center Joint Stock Company	77,420,000,000	-	(i)	77,420,000,000	-	(i)
<i>Investment in joint venture and associate companies</i>	153,300,000,000	(2,445,533,312)		153,300,000,000	(921,745,039)	
Huu Nghi Medicare Clinic Joint Stock Company	14,700,000,000	(251,308,540)	(i)	14,700,000,000	(116,686,997)	(i)
Nghe An Clinic Joint Stock Company	10,500,000,000	(128,802,140)	(i)	10,500,000,000	(35,878,195)	(i)
Ba Dinh Clinic Joint Stock Company	10,500,000,000	(733,171,047)	(i)	10,500,000,000	(459,037,548)	(i)
Phap Van Golab Testing Center Joint Stock Company	10,500,000,000	(157,963,599)	(i)	10,500,000,000	(31,339,259)	(i)
Golab Go Vap Testing Center Joint Stock Company	10,500,000,000	(89,454,626)	(i)	10,500,000,000	(29,123,121)	(i)
Bac Lieu Golab Testing Center Joint Stock Company	10,500,000,000	(116,473,996)	(i)	10,500,000,000	(33,757,173)	(i)
Tien Giang Golab Testing Center Joint Stock Company	10,500,000,000	(50,369,019)	(i)	10,500,000,000	(22,457,100)	(i)
Golab Binh Duong Testing Center Joint Stock Company	10,500,000,000	(101,419,461)	(i)	10,500,000,000	(12,406,284)	(i)
Golab Ha Giang Testing Center Joint Stock Company	14,700,000,000	(78,149,650)	(i)	14,700,000,000	(3,748,697)	(i)
Ninh Binh Golab Testing Center Joint Stock Company	14,700,000,000	(193,671,221)	(i)	14,700,000,000	(66,206,661)	(i)
Golab Vung Tau Testing Center Joint Stock Company	14,700,000,000	(424,394,544)	(i)	14,700,000,000	(83,265,549)	(i)

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

	Closing balance			Opening balance		
	Historical cost VND	Provision VND	Fair value VND	Historical cost VND	Provision VND	Fair value VND
Famicare Phap Van Joint Stock Company	10,500,000,000	(61,732,351)	(i)	10,500,000,000	(12,655,367)	(i)
Tuyen Quang Famicare Joint Stock Company	10,500,000,000	(58,623,118)	(i)	10,500,000,000	(15,183,088)	(i)
	1,408,040,000,000	(87,701,722,675)		1,437,440,000,000	(37,637,325,820)	

(i) The Company has not determined the fair value of these financial investments because the Vietnam Accounting Standards and the Vietnamese Corporate Accounting Regime currently do not have specific guidance on determining fair value.

Summary of the operation of subsidiaries and associated companies:

Name of Investment Company	Relationship	Place of establishment and operation	Ratio of direct and indirect benefits	Voting Rights Ratio	Main Activities
Viet My Hospital Investment Joint Stock Company	Subsidiaries	No. 307 Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province	83.33%	83.33%	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiaries	Lot A15, Nam Son Industrial Cluster, Nam Son Commune, Ba Che Commune, Quang Ninh Province	99%	99%	Manufacture of medicines, medicinal chemicals and medicinal materials. Manufacture of ovens, smelting furnaces and kilns
Golab Ung Bi Testing Center Joint Stock Company	Subsidiaries	Group 4, Zone 4, Bai Chay Ward, Quang Ninh Province	98%	98%	General and Specialty Clinics
Song Hau New Technology Research and Application Joint Stock Company	Subsidiaries	Song Hau Industrial Park – Phase 1, Chau Thanh Commune, Can Tho City	98%	98%	Manufacture of ovens, smelting furnaces and kilns

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

Summary of the operation of subsidiaries and associated companies:

Name of Investment Company	Relationship	Place of establishment and operation	Ratio of direct and indirect benefits	Voting Rights Ratio	Main Activities
Vietnam National Software Manufacturing Joint Stock Company	Subsidiaries	No. 36 BT5 Phap Van - Tu Hiep Urban Area, Hoang Mai Ward, Hanoi City	98%	98%	Microcomputer Programming
Leopard Solutions Joint Stock Company	Subsidiaries	No. 34, Street 79, Hamlet Dinh, Cu Chi Commune, Ho Chi Minh City	75%	75%	Microcomputer Programming
Ha Dong Clinic Joint Stock Company	Subsidiaries	3rd Floor, No. 1 Phuc Thinh Street, Cau Bieu, Kien Hung Ward, Hanoi City	98%	98%	General, specialty, and dental clinics
Hoa Binh Clinic Joint Stock Company	Subsidiaries	1st Floor, House No. 83, Cu Chinh Lan Street, Hoa Binh Ward, Phu Tho Province	98%	98%	General, specialty, and dental clinics
Viet Tri Clinic Joint Stock Company	Subsidiaries	No. 307, Nguyen Du Extended Street, Nong Trang Ward, Phu Tho Province	98%	98%	General, specialty, and dental clinics
Gia Lam High-tech Clinic Joint Stock Company	Subsidiaries	18 BT5 Phap Van - Tu Hiep Urban Area, Yen So Ward, Hanoi City	98%	98%	General, specialty, and dental clinics
Can Tho Medicare Clinic Joint Stock Company	Subsidiaries	No. 408 Nguyen Van Cu Street, An Binh Ward, Can Tho City, Vietnam	98%	98%	General, specialty, and dental clinics
Hau Giang Medicare Clinic Joint Stock Company	Subsidiaries	No. 16, 1st Floor, Street No. 14, Area 4, Vi Thanh Ward, Can Tho City	98%	98%	General, specialty, and dental clinics
Soc Trang Medicare Clinic Joint Stock Company	Subsidiaries	1st Floor, No. 438 Le Duan Street, Hamlet 4, Phu Loi Ward, Can Tho City	98%	98%	General, specialty, and dental clinics
Golab Nga Bai Testing Center Joint Stock Company	Subsidiaries	No. 222, 30/4 Street, Area 5, Nga Bai Ward, Can Tho City	98%	98%	General, specialty, and dental clinics
Huu Nghi Medicare Clinic Joint Stock Company	Affiliates	No. 179 Giai Phong Street, Bach Mai Ward, Hanoi City	49%	49%	General, specialty, and dental clinics
Nghe An Clinic Joint Stock Company	Affiliates	1st Floor, No. 68, Ho Tong Thoc Street, Block 13, Vinh Phu Ward, Nghe An Province	35%	35%	General, specialty, and dental clinics

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

Summary of the operation of subsidiaries and associated companies:

Name of Investment Company	Relationship	Place of establishment and operation	Ratio of direct and indirect benefits	Voting Rights Ratio	Main Activities
Ba Dinh Clinic Joint Stock Company	Affiliates	No. 37A Maternity Slope, De La Thanh Street, Lang Ward, Hanoi City	49%	49%	General, specialty, and dental clinics
Phap Van Golab Testing Center Joint Stock Company	Affiliates	1st Floor, Lot BT 5, No. 18 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35%	35%	General, specialty, and dental clinics
Golab Go Vap Testing Center Joint Stock Company	Affiliates	1st Floor, No. 178 Nguyen Thai Son, Hanh Thong Ward, Ho Chi Minh City	35%	35%	General, specialty, and dental clinics
Bac Lieu Golab Testing Center Joint Stock Company	Affiliates	Ground Floor, No. 210, Ba Trieu Street, Bac Lieu Ward, Ca Mau Province	35%	35%	General, specialty, and dental clinics
Tien Giang Golab Testing Center Joint Stock Company	Affiliates	368A, Phuoc Hoa Hamlet, Trung An Ward, Dong Thap Province	35%	35%	General, specialty, and dental clinics
Golab Binh Duong Testing Center Joint Stock Company	Affiliates	634 Binh Duong Boulevard, Zone 5, Phu Loi Ward, Ho Chi Minh City	35%	35%	General, specialty, and dental clinics
Golab Ha Giang Testing Center Joint Stock Company	Affiliates	1st Floor, No. 75D Nguyen Thai Hoc Street, Group 16, Ha Giang 2 Ward, Tuyen Quang	49%	49%	General, specialty, and dental clinics
Ninh Binh Golab Testing Center Joint Stock Company	Affiliates	1st Floor, House No. 140, Tue Tinh Street, Hoa Lu Ward, Ninh Binh City	49%	49%	General, specialty, and dental clinics
Golab Vung Tau Testing Center Joint Stock Company	Affiliates	No. 745 Vo Van Kiet, Tam Long Ward, Ho Chi Minh City	49%	49%	General, specialty, and dental clinics
Famicare Phap Van Joint Stock Company	Affiliates	1st Floor, Lot BT 5, No. 17 Phap Van – Tu Hiep New Urban Area, Yen So Ward, Hanoi City	35%	35%	General, specialty, and dental clinics
Tuyen Quang Famicare Joint Stock Company	Affiliates	2nd Floor, No. 23, Hoa Lu Street, Group 01, Minh Xuan Ward, Tuyen Quang Province	35%	35%	General, specialty, and dental clinics

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.3 Short-term trade receivables

	Closing balance VND	Opening balance VND
Can Tho Testing and Environment Center Joint Stock Company	-	45,502,587,900
LOU Investment Joint Stock Company	-	18,302,003,421
Golab Ha Tinh Testing Center Joint Stock Company	1,149,807,175	4,385,784,500
Hai Phong Golab Testing Center Joint Stock Company	1,120,000,000	2,932,070,200
Vinh Yen Golab Testing Center Joint Stock Company	1,252,791,156	-
Receivables from other customers	15,270,498,949	82,247,898,454
	18,793,097,280	153,370,344,475

Receivables from related customers: Details in Explanation 6.2

4.4 Short-term prepayments to suppliers

	Closing balance VND	Opening balance VND
LOU Investment Joint Stock Company	7,719,000,000	-
Kanpeki Japan Corporation	5,518,853,693	3,769,563,726
High-tech Medical Environment Co., Ltd.	3,430,000,000	-
Nha Trang Medical Hi-Tech Application Joint Stock Company (*)	-	5,000,000,000
Pay upfront to other merchants	1,089,150,011	754,786,788
	17,757,003,704	9,524,350,514

(*) It is an advance for the purpose of purchasing machinery, software, and medical equipment for production and business activities. However, due to the overdue time for supplying the machine, the parties came to cancel the contract and refund the money. The company has recovered the entire amount of money advanced.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

4.5 Other receivables

4.5.1 Other short-term receivables

	Closing balance		Opening balance	
	Values	Provision	Values	Provision
	VND	VND	VND	VND
Advance	-	-	169,775,746	-
Escrow, escrow	1,642,935,141	-	937,864,916	-
Dividends and profits to be distributed by Vietnam National Software Manufacturing Joint Stock Company	-	-	5,000,000,000	-
Phu Tho Obstetrics and Pediatrics Hospital (*)	43,500,000,000	-	-	-
	45,142,935,141	-	6,107,640,662	-

4.5.2 Other long-term receivables

	Closing balance		Opening balance	
	Values	Provision	Values	Provision
	VND	VND	VND	VND
Phu Tho Obstetrics and Pediatrics Hospital (*)	125,727,000,000	-	-	-
Total	125,727,000,000	-	-	-

(*) According to contract No. 01/2025/HDCN/SARA-VIETMY dated February 15th, 2025, the Company has received the transfer of the contributed capital of Sara Vietnam Joint Stock Company to Phu Tho Provincial General Hospital to invest in the construction of the Obstetrics and Pediatrics Center of Phu Tho Provincial General Hospital now Phu Tho Obstetrics and Pediatrics Hospital worth VND 204,227,000,000 with a transfer price of VND 204,227,000,000. However, according to the Resolution of the Board of Directors No. 1604/NQ-HDQT dated April 16th, 2025, the Company decided to withdraw capital ahead of schedule from Phu Tho Obstetrics and Pediatrics Hospital. On April 21st, 2025, the Company and Phu Tho Obstetrics and Pediatrics Hospital signed an appendix to contract No. 05 on early capital withdrawal. Accordingly, the Hospital will refund to the Company the amount contributed according to the roadmap from 2025 to 2028. Up to the time of issuance of this report, the Hospital has transferred 57 billion VND to the Company.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.6 Inventories

	Closing balance		Opening balance	
	Values	Provision	Values	Provision
	VND	VND	VND	VND
Merchandise	16,284,033,892	-	10,357,695,277	-
	16,284,033,892	-	10,357,695,277	-

4.7 Prepaid expenses

4.7.1 Short-term prepaid expenses

	Closing balance	Opening balance
	VND	VND
Tools, tools	55,482,529	-
Miscellaneous	34,999,997	-
	90,482,526	-

4.7.2 Long-term prepaid expense

	Closing balance	Opening balance
	VND	VND
Miscellaneous	25,436,250	13,355,630
	25,436,250	13,355,630

4.8 Tangible fixed assets

	Machinery and equipment	Total
	VND	VND
HISTORICAL COST		
Opening balance	50,034,090,809	50,034,090,809
Increase in the year	5,178,400,000	5,178,400,000
- Completed construction investment	4,030,000,000	4,030,000,000
- Purchase for the year	1,148,400,000	1,148,400,000
Decrease in the year	(352,200,000)	(352,200,000)
- Liquidation and sale	(352,200,000)	(352,200,000)
Closing balance	54,860,290,809	54,860,290,809
ACCUMULATED DEPRECIATION		
Opening balance	23,355,123,651	23,355,123,651
Increase in the year	4,769,456,311	4,769,456,311
- Depreciation in the year	4,769,456,311	4,769,456,311
Decrease in the year	(352,200,000)	(352,200,000)
- Liquidation and sale	(352,200,000)	(352,200,000)
Closing balance	27,772,379,962	27,772,379,962
NET BOOK VALUE		
Opening balance	26,678,967,158	26,678,967,158
Closing balance	27,087,910,847	27,087,910,847

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

The historical cost of tangible fixed assets is machinery and equipment that are being pledged and mortgaged for a loan at Viet Capital Commercial Joint Stock Bank with an amount of VND 38,916,611,293.

4.9 Intangible fixed assets

	<i>Software Programs VND</i>	<i>Total VND</i>
HISTORICAL COST		
Opening balance	59,564,895,987	59,564,895,987
Closing balance	59,564,895,987	59,564,895,987
ACCUMULATED DEPRECIATION		
Opening balance	20,811,796,801	20,811,796,801
Increase in the year	5,942,739,588	5,942,739,588
- Depreciation in the year	5,942,739,588	5,942,739,588
Closing balance	26,754,536,389	26,754,536,389
NET BOOK VALUE		
- At the beginning of the year	<u>38,753,099,186</u>	<u>38,753,099,186</u>
- At the end of the year	<u>32,810,359,598</u>	<u>32,810,359,598</u>

The Company's intangible fixed asset is the PACS software system:

The PACS system is a RIS – PACS medical image storage and transmission system that has been synchronously installed by the Company to serve medical examination and treatment, diagnosis by imaging and attached hardware installed at medical facilities (General Hospital, Medical centers of provinces/cities) according to the contract of cooperation agreement, installation, use, trial or business cooperation between the Company and medical facilities and has been accepted and handed over and put into operation by the medical facilities.

However, due to some problems with the payment mechanism and unit price of cooperation contracts, the Company has not fully identified and evaluated the benefits obtained from these business cooperation contracts. Currently, the Company is mainly collecting fees for providing maintenance and maintenance services for machinery and equipment as well as 24/24 technical support fees for the PACS system.

4.10 Unfinished basic construction

	<i>Closing balance VND</i>	<i>Opening balance VND</i>
Procurement of fixed assets		
+ Machine systems at hospitals	2,954,487,128	2,953,624,566
+ PACS system at health centers	17,737,378,342	17,737,378,342
	<u>20,691,865,470</u>	<u>20,691,002,908</u>

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.11 Provision for short-term doubtful debts

	Closing balance			Opening balance		
	Historical cost VND	Provision VND	Fair value VND	Historical cost VND	Provision VND	Fair value VND
Total value of receivables, overdue but difficult to recover						
<i>Customer receivables</i>						
- National Lung Hospital	171,239,842	171,239,842	-	171,239,842	171,239,842	-
- Hau Giang Tuberculosis and Lung Disease Hospital	35,168,802	35,168,802	-	35,168,802	35,168,802	-
- Gia Rai Regional Medical Center	27,496,482	27,496,482	-	27,496,482	27,496,482	-
- Phu Tho Provincial General Hospital	25,420,000	25,420,000	-	25,420,000	25,420,000	-
	<u>259,325,126</u>	<u>259,325,126</u>	<u>-</u>	<u>259,325,126</u>	<u>259,325,126</u>	<u>-</u>

4.12 Short-term trade payables

	Closing balance		Opening balance	
	Outstanding balance VND	Amount can be paid VND	Outstanding balance VND	Amount can be paid VND
Branch of Duy Minh Equipment Co., Ltd.	-	-	650,444,922	650,444,922
Huong Duong Science and Technology Co., Ltd.	356,213,750	356,213,750	3,900,000	3,900,000
JWB Co., Ltd	298,643,120	298,643,120	298,643,120	298,643,120
Other merchant payables	262,478,294	262,478,294	196,023,634	196,023,634
	<u>917,335,164</u>	<u>917,335,164</u>	<u>1,149,011,676</u>	<u>1,149,011,676</u>

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

4.13 Taxes and other payables to State budget

	Opening balance		Arising in the year		Closing balance	
	Opening receivable	Opening payables	Payables in the year	Actual payment in the year	Closing receivables	Tax payable at the end of the year
	VND	VND	VND	VND	VND	VND
Value-added tax	887,523,548	-	917,746,661	1,805,270,209	-	-
Corporate Income Tax	-	200,000,000	200,000,000	-	-	-
Personal Income Tax	11,195,625	-	117,523,679	99,574,562	29,144,742	-
Fees, charges and other payables	-	-	55,723,969	61,887,397	-	6,163,428
	898,719,173	200,000,000	1,290,994,309	1,966,732,168	29,144,742	6,163,428

The Company's tax finalization will be subject to the inspection of the tax authorities. Because the application of tax laws and regulations to various types of transactions can be interpreted in different ways, the amount of tax presented on the Separate Financial Statements may be changed at the discretion of the tax authorities.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.14 Accrued expenses

4.14.1 Short-term expenses

	Closing balance	Opening balance
	VND	VND
Interest expense	23,968,555,935	19,438,461,246
Other advance deductions	-	322,000,000
	23,968,555,935	19,760,461,246

4.15 Other payables

4.15.1 Other short-term payables

	Closing balance	Opening balance
	VND	VND
Social insurance, health insurance, unemployment insurance	33,984,000	-
Payable dividends (*)	75,924,090,000	75,924,090,000
Other payables and payables	7,480,400	7,180,000
	75,965,554,400	75,931,270,000

(*) The 2019 dividend payable to shareholders according to the list of shareholders closed on 12/01/2021. Resolution No. 2502/NQ-HDQT dated 25/02/2025 of the Board of Directors on changing the time of dividend payment in 2019. Accordingly, the dividend payment time is as follows: 1st payment on 28/01/2026, 2nd installment payment on 28/7/2026.

The reason for the change: The company is promoting the expansion of production and business activities and investing in equipment and machinery for important projects. To ensure progress, the Company uses available funds to order the necessary equipment.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

4.16 Borrowings and finance lease liabilities

4.16.1 Short-term borrowings and finance lease liabilities

	Opening balance		During the year		Closing balance	
	Outstanding balance	Amount can be paid	Increase	Decrease	Outstanding balance	Amount can be paid
	VND	VND	VND	VND	VND	VND
Short-term loans	24,625,095,827	24,625,095,827	-	1,499,000,000	23,126,095,827	23,126,095,827
Viet Capital Commercial Joint Stock Bank (*)	24,625,095,827	24,625,095,827	-	1,499,000,000	23,126,095,827	23,126,095,827
Short-term financial loans and leases	24,625,095,827	24,625,095,827	-	1,499,000,000	23,126,095,827	23,126,095,827

(*) Loans under Credit Agreement No. 0041900059900 dated 28/11/2019; Agreement amended and supplemented on 06/07/2021 on the adjustment of the principal repayment schedule. Loan amount: 40,000,000,000 VND; Loan purpose: Purchase of medical machinery and equipment for production and business activities; Loan interest rate: 11.5%/year; Loan term: 48 months. Security measure: medical machinery and equipment under the Mortgage Contract No. 0041900060000 dated 28/11/2019.

At the time of issuance of this report, the above debt was overdue. The time to apply for debt extension according to the Company's Official Letter No. 05/2024/CV-AMV is October 2024 and has been approved by Viet Capital Commercial Joint Stock Bank according to Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, up to now, the Company has not paid off the above principal debt, the Company is continuing to work with the Bank to apply for a debt extension.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

4.17 Owner's equity

4.17.1 Changes in owner's equity

	<i>Owner's contributed capital</i>	<i>Equity surplus</i>	<i>Undistributed profit after tax</i>	<i>Total</i>
	<i>VND</i>	<i>VND</i>	<i>VND</i>	<i>VND</i>
Balance at the beginning of the previous year	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
- Losses in the previous year	-	-	(12,651,723,096)	(12,651,723,096)
Balance at the end of the previous year	<u>1,311,056,500,000</u>	<u>(395,300,000)</u>	<u>234,243,514,791</u>	<u>1,544,904,714,791</u>
Balance at the beginning of this year	1,311,056,500,000	(395,300,000)	234,243,514,791	1,544,904,714,791
- Losses this year	-	-	(42,910,980,816)	(42,910,980,816)
Balance at the end of this year	<u>1,311,056,500,000</u>	<u>(395,300,000)</u>	<u>191,332,533,975</u>	<u>1,501,993,733,975</u>

4.17.2 Details of the owner's capital contribution

	<i>Closing balance</i>		<i>Opening balance</i>	
	<i>Actual capital contribution</i>	<i>Rate</i>	<i>Actual capital contribution</i>	<i>Rate</i>
	<i>VND</i>	<i>%</i>	<i>VND</i>	<i>%</i>
Other Shareholders	1,311,056,500,000	100,00%	1,311,056,500,000	100,00%
	<u>1,311,056,500,000</u>	<u>100,00%</u>	<u>1,311,056,500,000</u>	<u>100,00%</u>

4.17.3 Capital transactions with owners

	<i>This year VND</i>	<i>Previous year VND</i>
Owner's contributed capital		
At the beginning of the year	1,311,056,500,000	1,311,056,500,000
Increase in year	-	-
Decrease in year	-	-
At the end of the year	1,311,056,500,000	1,311,056,500,000
Distributed dividends and profit	-	-

4.17.4 Share

	<i>Closing balance Stocks</i>	<i>Opening balance Stocks</i>
- Quantity of authorized issuing shares	131,105,650	131,105,650
- Quantity of issued shares to the public	131,105,650	131,105,650
+ Common shares	131,105,650	131,105,650
- Quantity of shares repurchased	-	-
+ Common shares	-	-
- Quantity of outstanding shares in circulation	131,105,650	131,105,650
+ Common shares	131,105,650	131,105,650

Par value of shares outstanding: 10,000 VND/share.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

5 SUPPLEMENTARY INFORMATION FOR ITEMS PRESENTED IN THE SEPARATE INCOME STATEMENT

5.1 Revenue from sales of goods and rendering of services

	This year VND	Previous year VND
Revenue from sales goods and rendering of services	26,092,083,075	169,364,910,851
	26,092,083,075	169,364,910,851

Revenue of related parties: details in Exhibit 6.2

5.2 Revenue deductions

	This year VND	Previous year VND
Bounced sales	329,337,871	-
	329,337,871	-

5.3 Cost of goods sold and services rendered

	This year VND	Previous year VND
Cost of goods sold and services rendered	23,253,299,467	160,394,730,660
	23,253,299,467	160,394,730,660

5.4 Financial income

	This year VND	Previous year VND
Interest on deposits and loans	781,662	513,202
Dividends are distributed profits	17,009,339,331	10,000,000,000
	17,010,120,993	10,000,513,202

5.5 Financial expense

	This year VND	Previous year VND
Interest expense	4,530,094,689	5,638,032,048
Setting aside/reversing investment loss provisions	50,064,396,855	24,226,811,482
	54,594,491,544	29,864,843,530

5.6 Selling expense

	VND	VND
Labour expenses	133,333,326	295,095,140
Expenses of outsourcing services	2,080,000	25,977,202
	135,413,326	321,072,342

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

5.7 General and administrative expense

	This year VND	Previous year VND
Labour expenses	5,723,271,009	3,142,836,806
Office Supplies Cost	48,875,997	29,931,820
Depreciation expenses	5,992,428	5,992,428
Tax, Charge, Fee	7,000,000	6,000,000
Provision expenses/ Reversal of provision expenses	-	183,949,843
Expenses of outsourcing services	1,734,911,203	1,808,758,235
Other expenses in cash	194,585,521	148,396,815
	7,714,636,158	5,325,865,947

5.8 Other income

	This year VND	Previous year VND
Interest on liquidation and sale of fixed assets	140,000,000	3,903,888,904
Other income	227,540	20,416,672
	140,227,540	3,924,305,576

5.9 Other expenses

	This year VND	Previous year VND
Penalties for late payment of taxes and insurance	51,444,280	34,940,246
Other expenses	74,789,778	-
	126,234,058	34,940,246

5.10 Current corporate income tax expense

	This year VND	Previous year VND
Accounting profit before tax	(42,910,980,816)	(12,651,723,096)
- Upward adjustments	4,017,895,187	3,926,601,375
+) <i>Non-deductible expenses</i>	126,234,058	34,940,246
+) <i>Depreciation expenses of fixed assets not in service of production and business</i>	3,891,661,129	3,891,661,129
- Reduced adjustments	17,009,339,331	10,000,000,000
+) <i>Dividends and profits are distributed</i>	17,009,339,331	10,000,000,000
Profits for corporate income tax calculation	(55,902,424,960)	(18,725,121,721)
Income from business contracts is subject to the tax rate of 20%	(55,902,424,960)	(18,725,121,721)
Estimated corporate income tax payable	-	-
CIT expenses from business contracts are subject to a tax rate of 20%	-	-
Estimated corporate income tax payable	-	-

The Company's tax reports will be subject to the inspection of the tax authorities. As the application of tax laws and regulations can be interpreted in a variety of ways, the amount of tax presented on separate financial statements may be subject to change at the discretion of the tax authorities

5.11 Business and productions cost by items

	This year VND	Previous year VND
Cost of raw materials, materials, tools	48,875,997	29,931,820
Labour expenses	5,856,604,335	3,437,931,946
Depreciation expenses	10,712,195,899	9,667,514,548
Provision expenses/ Reversal of provision expenses	-	183,949,843
Expenses of outsourcing services	1,736,991,203	1,835,935,437
Other expenses in cash	201,585,521	154,396,815
	18,556,252,955	15,309,660,409

6 OTHER INFORMATION

6.1 Events arising after the end of the fiscal year

In addition to the above-mentioned events, the Company's Board of Directors affirms that there are no extraordinary events that occur after the end of the financial year that affect the Company's financial situation and operations that need to be adjusted or presented in this separate financial statement.

6.2 Transactions and balances with related parties

Stakeholders with the Company include: key management members, individuals related to key management members and other stakeholders.

6.2.1 Transactions and balances with key management members and related individuals with key management members.

Key management members include: members of the Board of Directors and members of the Board of Directors. Individuals who are related to key management members are close family members of key management members.

Shareholders	Relationship
Mrs. Dang Nhi Nuong	Company Director

Income of key management members

The total income of key management members enjoyed in the year is as follows:

	Title	This year VND	Previous year VND
Mrs. Dang Nhi Nuong	Director	261,500,000	261,500,000
		261,500,000	261,500,000

Transactions with key management members and individuals related to key management members are as follows:

During the year, the Company did not incur any transactions with related parties.

Balances with key management members and individuals related to key management members

During the year, the Company did not incur a balance with related parties.

6.2.2 Transactions and balances with other shareholders

Other shareholders with the Company include: subsidiaries, affiliates, individuals with direct or indirect voting rights in the Company and their close family members, businesses managed by key employees and individuals with direct or indirect voting rights of the Company and its constituents. in their families.

Other Shareholder List

Shareholders	Relationship
Viet My Hospital Investment Joint Stock Company	Subsidiaries
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiaries
Uong Bi Golab Testing Center Joint Stock Company	Subsidiaries
Song Hau New Technology Research and Application Joint Stock Company	Subsidiaries
Vietnam National Software Manufacturing Joint Stock Company	Subsidiaries
Leopard Solutions Joint Stock Company	Subsidiaries
Ha Dong Clinic Joint Stock Company	Subsidiaries
Hoa Binh Clinic Joint Stock Company	Subsidiaries
Viet Tri Clinic Joint Stock Company	Subsidiaries
Gia Lam High-tech Clinic Joint Stock Company	Subsidiaries
Can Tho Medicare Clinic Joint Stock Company	Subsidiaries
Soc Trang Medicare Clinic Joint Stock Company	Subsidiaries
'Hau Giang Medicare Clinic Joint Stock Company	Subsidiaries
Nga Bai Golab Testing Center Joint Stock Company	Subsidiaries
Huu Nghi Medicare Clinic Joint Stock Company	Affiliates
Nghe An Clinic Joint Stock Company	Affiliates
Ba Dinh Clinic Joint Stock Company	Affiliates
Phap Van Golab Testing Center Joint Stock Company	Affiliates
Golab Go Vap Testing Center Joint Stock Company	Affiliates
Bac Lieu Golab Testing Center Joint Stock Company	Affiliates
Tien Giang Golab Testing Center Joint Stock Company	Affiliates
Golab Binh Duong Testing Center Joint Stock Company	Affiliates
Golab Ha Giang Testing Center Joint Stock Company	Affiliates
Ninh Binh Golab Testing Center Joint Stock Company	Affiliates
Golab Vung Tau Testing Center Joint Stock Company	Affiliates
Famicare Phap Van Joint Stock Company	Affiliates
Tuyen Quang Famicare Joint Stock Company	Affiliates
Famicare Thu Duc Joint Stock Company	Indirect Ownership Subsidiaries
Nha Be Medicare Clinic Joint Stock Company	Indirect Ownership Subsidiaries
Famicare Vinh Yen Joint Stock Company	Indirect Ownership Subsidiaries

Transactions with other shareholders

In this year, there are mainly business operations with related companies as follows:

Purchase of goods and services	This year VND
PK Medicare Hau Giang Joint Stock Company	4,030,000,000
Sale of goods and services	This year VND
Viet Tri Clinic Joint Stock Company	171,800,668
Nghe An Clinic Joint Stock Company	140,158,906
Phap Van Golab Testing Center Joint Stock Company	35,000,000
Ninh Binh Golab Testing Center Joint Stock Company	69,449,810

Balance of accounts receivable/ (payable) with other related parties

	Closing balance VND	Opening balance VND
Receivables for short-term loans	-	500,000,000
Golab Binh Duong	-	500,000,000
Short-term customer receivables	11,689,578,182	82,715,368,400
Huu Nghi Medicare Clinic Joint Stock Company	-	244,200,000
Phap Van Golab Testing Center Joint Stock Company	-	242,000,000
Hai Phong Golab Testing Center Joint Stock Company	1,120,000,000	3,022,070,200
Golab Testing Center Joint Stock Company District 5	1,120,000,000	-
Golab Da Nang Testing Center Joint Stock Company	1,120,000,000	-
Hai Duong Golab Testing Center Joint Stock Company	1,120,000,000	7,479,494,700
Hung Yen Golab Testing Center Joint Stock Company	-	7,333,194,700
Thai Binh Golab Testing Center Joint Stock Company	1,120,000,000	-
Tan An Golab Testing Center Joint Stock Company	-	2,822,420,200
Dong Thap Golab Testing Center Joint Stock Company	-	2,848,270,200
Vinh Long Golab Testing Center Joint Stock Company	-	2,848,270,200
Famicare Vinh Long Joint Stock Company	-	7,305,694,700
Golab An Giang Testing Center Joint Stock Company	-	2,805,370,200
Famicare Kien Giang Joint Stock Company	-	4,505,384,500
Golab Kien Giang Testing Center Joint Stock Company	-	6,847,870,200
Bac Ninh Golab Testing Center Joint Stock Company	-	7,348,594,700
Vinh Phuc Golab Testing Center Joint Stock Company	-	7,494,884,500
Vinh Yen Golab Testing Center Joint Stock Company	1,252,791,156	-
Ninh Binh Golab Testing Center Joint Stock Company	36,172,300	42,900,000
Thanh Hoa Golab Testing Center Joint Stock Company	1,120,000,000	-
Nghe An Clinic Joint Stock Company	110,416,851	-
Golab Ha Tinh Testing Center Joint Stock Company	1,149,807,175	4,575,784,500
Famicare Quang Binh Joint Stock Company	-	4,505,384,500
Golab Quang Binh Testing Center Joint Stock Company	1,120,000,000	3,043,210,200
Golab Bien Hoa Testing Center Joint Stock Company	-	4,042,500,000
Golab Binh Dinh Testing Center Joint Stock Company	1,120,000,000	-
Golab Gia Lai Testing Center Joint Stock Company	-	2,832,870,200
Viet My Hospital Investment Joint Stock Company	-	2,835,000,000
Viet Tri Clinic Joint Stock Company	180,390,700	-
Other long-term receivables	-	5,000,000,000
Vietnam National Software Manufacturing Joint Stock Company	-	5,000,000,000

6.3 Irregularities and contingencies arising after the annuity

The Board of Directors affirms that, according to the Board of Directors, in terms of material aspects, there are no unusual events that occur after the end of the financial year that affect the Company's financial situation and operations that need to be adjusted or presented in this Financial Statement.

AMERICAN VIETNAMESE BIOTECH INC
NOTES TO THE SEPARATE FINANCIAL STATEMENTS (continued)

Form No. B 09 – DN

6.4 Comparison Information

Comparative data is the data on the Company's separate financial statements for the fiscal year ended December 31, 2024 which have been audited by Nhan Tam Viet Auditing Co., Ltd.



Preparer
Tran Hang Nga



Chief Accountant
Nguyen Thu Huyen



Director
Dang Nhi Nuong
Ho Chi Minh City, Vietnam
May 15, 2026

